Latest News and Press Releases

· Forsknings- och utvecklingskostnader 13,9 (15,2) MSEK · Resultat efter skatt -19,7 (-20,2) MSEK · Resultat per aktie -0,11 (-0,17) SEK · Bolaget hade ingen nettoomsättning under perioden ...

· Research and development costs amounted to SEK 10.7 (10.5) m · The loss after tax was SEK -14.9 (-13.9) m · Earnings per share were SEK -0.08 (-0.14) · The company had no net sales for the...

· Forsknings- och utvecklingskostnader 10,7 (10,5) MSEK · Resultat efter skatt -14,9 (-13,9) MSEK · Resultat per aktie -0,08 (-0,14) SEK · Bolaget hade ingen nettoomsättning under perioden ...

During 2009 ChronTech out licensed an exclusive right to the RAS® technology to the American company, Opsonic Therapeutics, and in return received 20% of outstanding Opsonic stock. Opsonic...

Under 2009 utlicensierade ChronTech sin RAS-teknologi till det amerikanska bolaget Opsonic Therapeutics, vilket gav ChronTech ett 20%-igt ägande i Opsonic. Opsonic har nu erhållit ett konvertibelt...

· Research and development costs amounted to SEK 6.7 (6.8) m · The loss after tax was SEK -9.6 (-9.0) m · Earnings per share were SEK -0.05 (-0.11) · The company had no net sales for the...

· Forsknings- och utvecklingskostnader 6,7 (6,8) MSEK · Resultat efter skatt -9,6 (-9,0) MSEK · Resultat per aktie -0,05 (-0,11) SEK · Bolaget hade ingen nettoomsättning under perioden ·...

· Research and development costs amounted to SEK 3.2 (3.8) m · The loss after tax was SEK -4.2 (-5.0) m · Earnings per share were SEK -0.02 (-0.06) · The company had no net sales for the...

· Forsknings- och utvecklingskostnader 3,2 (3,8) MSEK · Resultat efter skatt -4,2 (-5,0) MSEK · Resultat per aktie -0,02 (-0,06) SEK · Bolaget hade ingen nettoomsättning under perioden ·...

The Annual General Meeting of ChronTech Pharma AB was held in Stockholm on April 16th, 2012. Annual Report and discharge from liability The Company's Income Statement and Balance Sheet were adopted...